Apatinib and Etoposide Capsule Versus Apatinib in Patients With Platinum Resistant Ovarian Cancer
Status:
Not yet recruiting
Trial end date:
2021-06-01
Target enrollment:
Participant gender:
Summary
The study is conducted to evaluate the efficacy, safety and tolerability of apatinib (375 mg
qd) or apatinib (375 mg qd) and etoposide capsule (50 mg/d, d1-14, q3w) in subjects with
platinum resistant or refractory ovarian cancer compared with apatinib (375 mg qd).